Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 15/20 | 0.56 |
| ▸ | TDO2 | P48775 | 13/20 | 0.48 |
| ▸ | IDO2 | Q6ZQW0 | 10/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540351 | 0.85 | IDO1 (0.55) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL4586093 | 0.79 | APAF1 (0.71) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL4593229 | 0.78 | APAF1 (0.60) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL30639091 | 0.77 | APAF1 (0.61) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL26614118 | 0.77 | APAF1 (0.61) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL9233005 | 0.77 | APAF1 (0.58) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL26614207 | 0.76 | APAF1 (0.57) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL26858212 | 0.76 | TDO2 (0.70) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL26614284 | 0.75 | APAF1 (0.59) | APAF1IDO1TDO2IDO2NPC1 | |
| SCHEMBL9100596 | 0.75 | APAF1 (1.00) | APAF1IDO1TDO2IDO2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | APAF1 928/4885IDO1 20/4885TDO2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.